This may be of clinical and therapeutic relevance as MS and RA tend to be more frequently associated in the same patient [16] and TNF-inhibitors used for RA may exacerbate or induce de novo MS, while IFN-beta has been suspected to provoke RA. This evidence concerns the gene TNF and myeloid sarcoma.